Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results

Business Wire

Mon, Aug 4, 2025, 4:05 PM 22 min read

Revenue of $544.8 million, up 73% year-over-year in Q2 2025

Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025

Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025

Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335 million

SAN FRANCISCO, August 04, 2025--(BUSINESS WIRE)--Hims & Hers Health, Inc. ("Hims & Hers" or the "Company", NYSE: HIMS), the leading health and wellness platform, today announced financial results for the second quarter ended June 30, 2025, in a shareholder letter that is posted at investors.hims.com.

"It’s never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine," said Andrew Dudum, co-founder and CEO. "We believe we’re entering an exciting period of growth where we’ll enter new, high-impact specialties that bring millions of people in need of care into the market. We expect this broadening offering will transform our platform from a place where customers come to solve a single issue, to one where customers can proactively manage their overall health."

Yemi Okupe, CFO, stated, "We’re seeing consistent growth across our business as we continue to democratize access to precision care. In the second quarter, revenue grew 73% and Adjusted EBITDA more than doubled relative to the prior year; both were driven by robust growth in Subscribers utilizing personalized treatment plans. As we move into the second half of 2025, our focus is on investing in capabilities that will deepen the value customers can access on our platform. This includes plans to strengthen the personalization infrastructure in our pharmacies, to expand lab testing capabilities to further tailor care, and to grow our international presence in key markets."

Second Quarter 2025 Financial Highlights

• Revenue was $544.8 million for the second quarter of 2025 compared to $315.6 million for the second quarter of 2024, an increase of 73% year-over-year.

• Gross margin was 76% for the second quarter of 2025 compared to 81% for the second quarter of 2024.

• Net income was $42.5 million for the second quarter of 2025 compared to $13.3 million for the second quarter of 2024.

• Adjusted EBITDA was $82.2 million for the second quarter of 2025 compared to $39.3 million for the second quarter of 2024.

• Net cash used in operating activities was $(19.1) million for the second quarter of 2025 compared to net cash provided by operating activities of $53.6 million for the second quarter of 2024.

• Free Cash Flow was $(69.4) million for the second quarter of 2025 compared to $47.6 million for the second quarter of 2024.